TickerFacts.

Replimune Group, Inc. (REPL): Capital Expenditures

Annual figures by period end, from SEC filings.

$4.22M
Year ended 2026-03-31
$1.49M
Trailing 12 months to 2026-06-30
+23.0%
3-year compound annual growth
+12.0%
5-year compound annual growth
$6.69M2017-03-31: $238.0K2018-03-31: $136.0K2019-03-31: $2.60M2020-03-31: $6.54M2021-03-31: $2.39M2022-03-31: $2.34M2023-03-31: $2.27M2024-03-31: $5.66M2025-03-31: $6.69M2026-03-31: $4.22M$4.22M
2017-03-31 Capital Expenditures (USD) 2026-03-31
Period endedCapital ExpendituresChange YoYSource filing
2026-03-31$4.22M-36.8%2026-06-29, From 2025-04-01
2025-03-31$6.69M+18.1%2026-06-29, From 2024-04-01
2024-03-31$5.66M+149.4%2025-05-22, From 2023-04-01
2023-03-31$2.27M-2.8%2024-05-16, From 2022-04-01
2022-03-31$2.34M-2.3%2023-05-18, From 2021-04-01
2021-03-31$2.39M-63.4%2022-05-19, From 2020-04-01
2020-03-31$6.54M+151.5%2021-05-20, From 2019-04-01
2019-03-31$2.60Mn/m2020-06-03, From 2018-04-01
2018-03-31$136.0K-42.9%2020-06-03, From 2017-04-01
2017-03-31$238.0Kn/a2019-06-28, From 2016-04-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCapital ExpendituresChange YoY
Replimune Group, Inc. (REPL)2026-03-31$4.22M-36.8%
Prokidney Corp. (PROK)2025-12-31$15.20M-48.5%
Prime Medicine, Inc. (PRME)2025-12-31$4.53M-37.9%
Taysha Gene Therapies, Inc. (TSHA)2025-12-31$738.0K+97.3%
Fate Therapeutics Inc (FATE)2025-12-31$5.95M+715.5%
Kodiak Sciences Inc. (KOD)2025-12-31$506.0K+34.9%
C4 Therapeutics, Inc. (CCCC)2025-12-31$607.0K+237.2%
LENZ Therapeutics, Inc. (LENZ)2025-12-31$827.0K+76.7%
Scilex Holding Co (SCLX)2025-12-31$133.0Kn/a

Compare REPL, PROK, PRME, TSHA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗